These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38488654)

  • 1. Blood monitoring during psoriasis treatment with biologics.
    Br J Dermatol; 2024 Mar; 190(4):e47. PubMed ID: 38488654
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [No Abstract]   [Full Text] [Related]  

  • 3. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
    Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
    G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life.
    Puig L; Morales-Múnera CE
    Eur J Dermatol; 2013; 23(3):407-8. PubMed ID: 23782978
    [No Abstract]   [Full Text] [Related]  

  • 5. A new approach in monitoring blood tests in anti-tumour necrosis factor-α therapies in psoriasis.
    Conti A; Paolinelli M
    Br J Dermatol; 2024 Mar; 190(4):463-464. PubMed ID: 38092026
    [No Abstract]   [Full Text] [Related]  

  • 6. A new era in the management of psoriasis? The biologics: facts and controversies.
    Ferrándiz C; Carrascosa JM; Boada A
    Clin Dermatol; 2010; 28(1):81-7. PubMed ID: 20082956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
    Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
    Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How can we manage the safety concerns associated with the increase in biologics for psoriasis?
    Silfvast-Kaiser A; Menter MA
    Expert Opin Drug Saf; 2020 Apr; 19(4):361-364. PubMed ID: 31951750
    [No Abstract]   [Full Text] [Related]  

  • 9. Costs of Common Psoriasis Medications, 2010-2014.
    James SM; Hill DE; Feldman SR
    J Drugs Dermatol; 2016 Mar; 15(3):305-8. PubMed ID: 26954315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
    Levine D; Strober BE
    Semin Cutan Med Surg; 2010 Mar; 29(1):28-34. PubMed ID: 20430305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.
    Carrascosa JM; van Doorn MB; Lahfa M; Nestle FO; Jullien D; Prinz JC
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1424-30. PubMed ID: 24841895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
    Lebwohl M; Bagel J; Gelfand JM; Gladman D; Gordon KB; Hsu S; Kalb RE; Kimball AB; Korman NJ; Krueger GG; Mease P; Morison WL; Paller A; Pariser DM; Ritchlin C; Strober B; Van Voorhees A; Weinstein GD; Young M; Horn L
    J Am Acad Dermatol; 2008 Jan; 58(1):94-105. PubMed ID: 17980456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ; Lebwohl MG
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of pediatric plaque psoriasis using biologics.
    Lansang P; Bergman JN; Fiorillo L; Joseph M; Lara-Corrales I; Marcoux D; McCuaig C; Pope E; Prajapati VH; Li SZJ; Landells I
    J Am Acad Dermatol; 2020 Jan; 82(1):213-221. PubMed ID: 31150699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics in pediatric psoriasis.
    Wang WM; Jin HZ
    J Dermatol; 2023 Apr; 50(4):415-421. PubMed ID: 36651087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental cost-effectiveness ratio analysis of biologic treatments for psoriasis at clinically significant evaluation time points.
    Puig L; López-Ferrer A; Vilarrasa E
    Actas Dermosifiliogr; 2014 Dec; 105(10):951-3. PubMed ID: 24836110
    [No Abstract]   [Full Text] [Related]  

  • 17. Biologics monitoring: incongruity between recommendations and clinician monitoring trends.
    Nadkarni A; Hyde K; Cardwell LA; Feldman SR
    J Dermatolog Treat; 2020 Aug; 31(5):450-451. PubMed ID: 29792371
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics.
    Choi YM; Adelzadeh L; Wu JJ
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e99-e101. PubMed ID: 26388307
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
    Zhang Z; Schmitt J; Wozel G; Kirch W
    Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psoriasis in the era of biologics].
    Torres T; Velho GC; Sanches M; Selores M
    Acta Med Port; 2010; 23(3):493-8. PubMed ID: 20654269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.